150 results
Page 5 of 8
8-K
EX-99.1
k9y87n88susmtazya
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.1
lav0zmqz pxmzrwt
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
EX-99.1
v92p50oip99w
13 Feb 20
Results of Operations and Financial Condition
7:06am
8-K
EX-99.1
hdh7 7as80495lo
25 Nov 19
Alkermes Completes Acquisition of Rodin Therapeutics
5:26pm
8-K
EX-99.1
yt66p
18 Nov 19
Alkermes to Acquire Rodin Therapeutics
7:16am
8-K
EX-99.1
342saonqnk47fw
30 Oct 19
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
7:43am
8-K
EX-99.1
uamwky1yw5x
23 Oct 19
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
7:05am
8-K
EX-99.1
s7axh5aj0e3t
13 Sep 19
Departure of Directors or Certain Officers
7:22am
8-K
EX-99.1
ylnqe5jywr3
30 Jul 19
Regulation FD Disclosure
7:46am
8-K
EX-99.1
0v11ma0
25 Jul 19
Alkermes Plc Reports Second Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
55dg 8q0z1yarmog70
15 Jul 19
Regulation FD Disclosure
7:33am
DEFA14A
4zrb15 20heh
15 May 19
Additional proxy soliciting materials
12:32pm
8-K
EX-99.1
5ds x4laby7kapdgo
25 Apr 19
Alkermes Plc Reports First Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
wyuokrru dcruw6
8 Apr 19
Alkermes Announces Departure of Jim Robinson
5:26pm
8-K
EX-99.1
dt3dmtxd4ede
14 Feb 19
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
3nvw445ov1kw
1 Feb 19
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
4:33pm
8-K
EX-99.1
8lcg1gqznpgo0
29 Nov 18
Alkermes Announces Positive Topline Results FromENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
7:17am
8-K
EX-99.1
uerhjdfxff9hf c02
2 Nov 18
Regulation FD Disclosure
12:00am